Commentary on “Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

Manfredi, Celeste; Bologna, Eugenio; Licari, Leslie Claire

doi:10.1038/s41443-023-00811-4

Int J Impot Res

2023

DOI: 10.1038/s41443-023-00811-4

|View full text |Cite

Commentary on “Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

Celeste Manfredi,

Eugenio Bologna,

Leslie Claire Licari

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Unveiling treatment horizons and contemporary perspectives in Peyronie’s disease – take home messages from Laurance A. Levine special issue

Levine

2024

Int J Impot Res

View full text Add to dashboard Cite

Unveiling treatment horizons and contemporary perspectives in Peyronie’s disease – take home messages from Laurance A. Levine special issue

Levine

2024

Int J Impot Res

View full text Add to dashboard Cite

Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

Durukan,

Jensen,

Fode

2024

Int J Impot Res

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Commentary on “Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

Cited by 2 publications

References 11 publications

Unveiling treatment horizons and contemporary perspectives in Peyronie’s disease – take home messages from Laurance A. Levine special issue

Unveiling treatment horizons and contemporary perspectives in Peyronie’s disease – take home messages from Laurance A. Levine special issue

Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

Contact Info

Product

Resources

About